The global congestive heart failure treatment devices market size was US$ 12.57 billion in 2021. The global congestive heart failure treatment devices market size is forecast to reach US$ 20.7 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.7% during the forecast period from 2022 to 2030.
A mechanical circulatory support device helps to treat congestive heart failure. Pacemakers, cardiac resynchronization therapy devices, implantable cardioverter defibrillators, and ventricular assist devices are examples of congestive heart failure therapeutic equipment. Implantable cardiac defibrillators are electronic devices that are implanted into the body. An ICD (implantable cardiac defibrillator) continuously monitors heart rhythm and, if it becomes abnormal, delivers a mild shock to the heart muscle. A ventricular assist device aids in the pumping of blood from the heart's lower chambers to the rest of the body.
Factors Influencing Market Growth
Impact Analysis of COVID-19
The COVID-19 outbreak had a negative impact on the growth of the global market. Adult heart surgery volumes dropped dramatically during the first wave of the COVID-19 pandemic, as per the Society of Thoracic Surgeons. A COVID-19 pandemic has put a strain on the global healthcare system. Several clinics and hospitals worldwide had to reconfigure to boost hospital capacity for COVID-19 patients. As a result, many non-essential surgical procedures had to cancel worldwide.
Regional Insights
North America garnered the major market share in 2021 and is forecast to maintain its dominance during the forecast period. As a result of the growing prevalence of cardiovascular surgeries, rising approvals for ventricular assist products, the existence of key players, and expansion in technology for healthcare.
Leading Competitors
The leading prominent companies profiled in the global congestive heart failure treatment devices market are:
Scope of the Report
The global congestive heart failure treatment devices market segmentation focuses on Product Type, End-user, and Region.
Segmentation based on Product Type
Segmentation based on End-user
Segmentation based on Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY PRODUCT TYPE
5.1 OVERVIEW
5.2 PACEMAKERS
5.3 CARDIAC RESYNCHRONIZATION THERAPY
5.4 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS
5.5 VENTRICULAR ASSIST DEVICES
6 GLOBAL CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY END-USER
6.1 OVERVIEW
6.2 HOSPITALS
6.3 AMBULATORY SURGICAL CENTERS
7 GLOBAL CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET, BY GEOGRAPHY
7.1 OVERVIEW
7.2 NORTH AMERICA
7.2.1 NORTH AMERICA MARKET SNAPSHOT
7.2.2 U.S.
7.2.3 CANADA
7.2.4 MEXICO
7.3 EUROPE
7.3.1 EUROPE MARKET SNAPSHOT
7.3.2 WESTERN EUROPE
7.3.2.1 THE UK
7.3.2.2 GERMANY
7.3.2.3 FRANCE
7.3.2.4 ITALY
7.3.2.5 SPAIN
7.3.2.6 REST OF WESTERN EUROPE
7.3.3 EASTERN EUROPE
7.3.3. 1 POLAND
7.3.3.2 RUSSIA
7.3.3.3 REST OF EASTERN EUROPE
7.4 ASIA PACIFIC
7.4.1 ASIA PACIFIC MARKET SNAPSHOT
7.4.2 CHINA
7.4.3 JAPAN
7.4.4 INDIA
7.4.5 AUSTRALIA & NEW ZEALAND
7.4.6 ASEAN
7.4.7 REST OF ASIA PACIFIC
7.5 MIDDLE EAST & AFRICA
7.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
7.5.2 UAE
7.5.3 SAUDI ARABIA
7.5.4 SOUTH AFRICA
7.5.5 REST OF MEA
7.6 SOUTH AMERICA
7.6.1 SOUTH AMERICA MARKET SNAPSHOT
7.6.2 BRAZIL
7.6.3 ARGENTINA
7.6.4 REST OF SOUTH AMERICA
8 GLOBAL CONGESTIVE HEART FAILURE (CHF) TREATMENT DEVICES MARKET COMPETITIVE LANDSCAPE
8.1 OVERVIEW
8.2 COMPANY MARKET RANKING
8.3 KEY DEVELOPMENT STRATEGIES
9 COMPANY PROFILES
9.1 ABBOT LABORATORIES
9.1.1 OVERVIEW
9.1.2 FINANCIAL PERFORMANCE
9.1.3 PRODUCT OUTLOOK
9.1.4 KEY DEVELOPMENTS
9.2 ABIOMED INCORPORATED
9.2.1 OVERVIEW
9.2.2 FINANCIAL PERFORMANCE
9.2.3 PRODUCT OUTLOOK
9.2.4 KEY DEVELOPMENTS
9.3 BERLIN HEART GMBH
9.3.1 OVERVIEW
9.3.2 FINANCIAL PERFORMANCE
9.3.3 PRODUCT OUTLOOK
9.3.4 KEY DEVELOPMENTS
9.4 BIOTRONIK SE AND CO. KG
9.4.1 OVERVIEW
9.4.2 FINANCIAL PERFORMANCE
9.4.3 PRODUCT OUTLOOK
9.4.4 KEY DEVELOPMENTS
9.5 BOSTON SCIENTIFIC CORPORATION
9.5.1 OVERVIEW
9.5.2 FINANCIAL PERFORMANCE
9.5.3 PRODUCT OUTLOOK
9.5.4 KEY DEVELOPMENTS
9.6 JARVIK HEART INCORPORATED
9.6.1 OVERVIEW
9.6.2 FINANCIAL PERFORMANCE
9.6.3 PRODUCT OUTLOOK
9.6.4 KEY DEVELOPMENTS
9.7 LEPU MEDICAL
9.7.1 OVERVIEW
9.7.2 FINANCIAL PERFORMANCE
9.7.3 PRODUCT OUTLOOK
9.7.4 KEY DEVELOPMENTS
9.8 MEDTRONIC PLC
9.8.1 OVERVIEW
9.8.2 FINANCIAL PERFORMANCE
9.8.3 PRODUCT OUTLOOK
9.8.4 KEY DEVELOPMENTS
9.9 MICROPORT SCIENTIFIC CORPORATION
9.9.1 OVERVIEW
9.9.2 FINANCIAL PERFORMANCE
9.9.3 PRODUCT OUTLOOK
9.5.4 KEY DEVELOPMENTS
9.10 OSYPKA MEDICAL GMBH
9.10.1 OVERVIEW
9.10.2 FINANCIAL PERFORMANCE
9.10.3 PRODUCT OUTLOOK
9.10.4 KEY DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved